Compare NXDT & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NXDT | SGHT |
|---|---|---|
| Founded | 2012 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 259.1M | 309.6M |
| IPO Year | N/A | 2021 |
| Metric | NXDT | SGHT |
|---|---|---|
| Price | $5.47 | $4.90 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $9.08 |
| AVG Volume (30 Days) | 157.8K | ★ 199.0K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 9.66% | N/A |
| EPS Growth | N/A | ★ 28.16 |
| EPS | ★ 0.99 | N/A |
| Revenue | N/A | ★ $77,363,000.00 |
| Revenue This Year | N/A | $11.67 |
| Revenue Next Year | N/A | $10.39 |
| P/E Ratio | $5.47 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.55 | $3.11 |
| 52 Week High | $5.95 | $9.24 |
| Indicator | NXDT | SGHT |
|---|---|---|
| Relative Strength Index (RSI) | 55.41 | 43.14 |
| Support Level | $4.35 | $4.76 |
| Resistance Level | $5.57 | $5.25 |
| Average True Range (ATR) | 0.23 | 0.32 |
| MACD | -0.00 | -0.08 |
| Stochastic Oscillator | 43.75 | 38.79 |
NexPoint Diversified Real Estate Trust is an externally advised REIT focused on the acquisition, asset management, development, and disposition of opportunistic, value-add investments in real estate properties throughout the United States. The company has two reportable segments: The Diversified reportable segment is focused on investing in various commercial real estate property types and across the capital structure, including but not limited to, equity, mortgage, debt, mezzanine debt and preferred equity. The Hospitality segment is focused on operating and renovating its U.S. located hospitality assets that meet its investment objective and criteria. Its Portfolio includes investments in the single-family rental, self-storage, office, hospitality, life science and multifamily sectors.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.